bluebird bio Inc (NAS:BLUE)
$ 0.405 0.0272 (7.2%) Market Cap: 78.75 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 01:00AM GMT
Release Date Price: $6.22 (-15.60%)
Andrew Obenshain
bluebird bio, Inc. - President, CEO & Director

(technical difficulty) we're really excited to be here after a pretty transformative year for bluebird. We now have -- 2 of the 4 gene therapies approved in the U.S. just in a year ago, we were still a clinical development company and now we are fully a commercial company. We were really excited to launch both SKYSONA for cerebral adrenoleukodystrophy this year and ZYNTEGLO for beta thalassemia and that was following 2 unanimous AdComs in June. So those are both FDA-approved right now. We're going to be launching lovo-cel for sickle cell disease -- or sorry, excuse me, filing with the FDA (technical difficulty) the infrastructure that we're building right now for ZYNTEGLO in the U.S. will support that launch. So really a completely new chapter in bluebird's history, we're now a commercial company.

Questions & Answers

Unidentified Analyst

Fantastic. So what's the most frequent (inaudible) and bear argument (technical difficulty) no it's been a very exciting time for you guys. Can you talk

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot